Skip to main content
SpringerLink
Log in

Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Dong-Si T, Gheuns S, Gangadharan A, Wenten M, Philip J, McIninch J et al (2015) Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neuro-Oncol 21(6):637–644. https://doi.org/10.1007/s13365-015-0316-4

  2. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO (2010) JC virus persistence following PML in MS patients treated with natalizumab. Ann Neurol 68(3):384–391. https://doi.org/10.1002/ana.22137

    Article  PubMed  PubMed Central  Google Scholar 

  3. Heopner R, Faissner S, Ellrichmann G, Schneider R, Gold R (2014) Rituximab post progressive multifocal leukoencephalopathy: a feasible therapeutic option in selected cases. Ther Adv Neurol Disord 7(6):289–291. https://doi.org/10.1177/1756285614556287

Download references

Author information

Authors and Affiliations

  1. Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti 154, 25018, Montichiari, Brescia, Italy

    Chiara Rosa Mancinelli, C. Scarpazza, N. De Rossi & R. Capra

  2. Multiple Sclerosis Centre, Sondrio Hospital, ASST Valtellina-Alto Lario, 23100, Sondrio, Italy

    G. Santuccio

Authors
  1. Chiara Rosa Mancinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Scarpazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Santuccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. De Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Capra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chiara Rosa Mancinelli.

Ethics declarations

Ethical approval

This study was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The retrospective analysis in anonymous form of patients’ data included within the Italian PML database was approved by the ethical committee of the Spedali Civili of Brescia.

Conflict of interest

Dr. Capra received consulting fees from Novartis, Biogen, and lecture fees and/or travel grants from Novartis, Biogen, Genzyme, and Sanofi-Aventis. Dr. De Rossi received speaker honoraria from Biogen and Teva and travel grants from Biogen, Teva, and Merck Serono. Dr. Mancinelli, Dr. Scarpazza, and Dr. Santuccio declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mancinelli, C.R., Scarpazza, C., Santuccio, G. et al. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?. Neurol Sci 39, 965–966 (2018). https://doi.org/10.1007/s10072-017-3228-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-017-3228-7

Search

Navigation